Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity

MM Schoonheim; LE Jonkman; AJC Eijlers; KA Meijer; J Killestein; JJG Geurts

Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity

MM Schoonheim, LE Jonkman, AJC Eijlers, KA Meijer, J Killestein, JJG Geurts

Research output: Contribution to conference › Poster › Academic

Original language	English
Publication status	Published - 1 Jul 2019
Event	5th Congress of the European Academy of Neurology - Oslo, Norway Duration: 29 Jun 2019 → 2 Jul 2019

Conference

Conference	5th Congress of the European Academy of Neurology
Abbreviated title	EAN
Country/Territory	Norway
City	Oslo
Period	29/06/2019 → 2/07/2019

Cite this

@conference{969f725dc04945bc9b384776fcfeed22,

title = "Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity",

author = "MM Schoonheim and LE Jonkman and AJC Eijlers and KA Meijer and J Killestein and JJG Geurts",

year = "2019",

month = jul,

day = "1",

language = "English",

note = "5th Congress of the European Academy of Neurology, EAN ; Conference date: 29-06-2019 Through 02-07-2019",

}

TY - CONF

T1 - Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity

AU - Schoonheim, MM

AU - Jonkman, LE

AU - Eijlers, AJC

AU - Meijer, KA

AU - Killestein, J

AU - Geurts, JJG

PY - 2019/7/1

Y1 - 2019/7/1

M3 - Poster

T2 - 5th Congress of the European Academy of Neurology

Y2 - 29 June 2019 through 2 July 2019

ER -